Cardiovascular events did not differ significantly across pituitary disease treatment groups
A retrospective study found no significant difference in cardiovascular events between groups. Untreated patients had higher mortality, but were also older and had more illnesses.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Major cardiovascular events did not differ significantly across the groups in this study of men with pituitary tumors. Untreated secondary hypogonadism was associated with higher mortality, but those patients were older and had more other illnesses. The findings do not prove testosterone treatment prevents death or that cardiovascular risks are equivalent between treatment groups.
The study was observational, and this brief uses only its abstract. Without event counts or confidence intervals, the nonsignificant cardiovascular result cannot rule out a clinically meaningful difference.
What researchers found
Major adverse cardiovascular events
Across men with testosterone-treated or untreated secondary hypogonadism and men without it; median follow-up 8.1 years, using multivariable logistic regression.
How events were studied
Researchers examined records from medical charts and provincial heart and stroke registries. Their analysis compared cardiovascular events among testosterone-treated and untreated men with secondary hypogonadism, and men without that condition.
Mortality needs separate interpretation
Untreated patients had a higher mortality risk than both comparison groups. Their older age and greater burden of illness complicate interpretation: this association cannot show that testosterone replacement itself improves survival.
The original publication
Secondary Hypogonadism and Effects of Testosterone Replacement Therapy on Cardiovascular Events.
Munro V, Law J, Matheson K et al.
J Clin Endocrinol Metab · 2026
- PubMed ID
- 41252267
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.